TAYSHA GENE THERAPIES INC (TSHA)
US8776191061 - Common Stock
Overall TSHA gets a fundamental rating of 2 out of 10. We evaluated TSHA against 587 industry peers in the Biotechnology industry. TSHA has a bad profitability rating. Also its financial health evaluation is rather negative. TSHA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TSHA had positive earnings in the past year.
TSHA had a negative operating cash flow in the past year.
TSHA had negative earnings in each of the past 5 years.
In the past 5 years TSHA always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -64.59%, TSHA is not doing good in the industry: 62.12% of the companies in the same industry are doing better.
TSHA has a worse Return On Equity (-148.88%) than 65.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.59% | ||
| ROE | -148.88% | ||
| ROIC | N/A |
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSHA has been increased compared to 1 year ago.
The debt/assets ratio for TSHA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.70, we must say that TSHA is in the distress zone and has some risk of bankruptcy.
TSHA has a Altman-Z score (-1.70) which is in line with its industry peers.
TSHA has a Debt/Equity ratio of 0.54. This is a neutral value indicating TSHA is somewhat dependend on debt financing.
The Debt to Equity ratio of TSHA (0.54) is worse than 73.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.7 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
TSHA has a Current Ratio of 4.08. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
TSHA has a Current ratio (4.08) which is in line with its industry peers.
A Quick Ratio of 4.08 indicates that TSHA has no problem at all paying its short term obligations.
With a Quick ratio value of 4.08, TSHA perfoms like the industry average, outperforming 46.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.08 | ||
| Quick Ratio | 4.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 104.15% over the past year.
Looking at the last year, TSHA shows a very strong growth in Revenue. The Revenue has grown by 518.56%.
EPS 1Y (TTM)104.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q370.59%
Revenue 1Y (TTM)518.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q44.16%
3.2 Future
Based on estimates for the next years, TSHA will show a very negative growth in Earnings Per Share. The EPS will decrease by -32.21% on average per year.
TSHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.80% yearly.
EPS Next Y-415.61%
EPS Next 2Y-140.18%
EPS Next 3Y-86.74%
EPS Next 5Y-32.21%
Revenue Next Year-41.29%
Revenue Next 2Y-34.04%
Revenue Next 3Y-53.03%
Revenue Next 5Y59.8%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.77, the valuation of TSHA can be described as rather expensive.
96.59% of the companies in the same industry are more expensive than TSHA, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of TSHA to the average of the S&P500 Index (27.73), we can say TSHA is valued slightly cheaper.
The Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.77 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TSHA's earnings are expected to decrease with -86.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-140.18%
EPS Next 3Y-86.74%
5. Dividend
5.1 Amount
No dividends for TSHA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TAYSHA GENE THERAPIES INC
NASDAQ:TSHA (5/3/2024, 7:23:00 PM)
After market: 2.52 -0.05 (-1.95%)2.57
-0.01 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap480.64M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.77 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.59% | ||
| ROE | -148.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.08 | ||
| Quick Ratio | 4.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)104.15%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-415.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)518.56%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y